iBio, Inc. (NASDAQ:IBIO) Given Consensus Rating of “Buy” by Analysts

Shares of iBio, Inc. (NASDAQ:IBIO) have earned an average recommendation of “Buy” from the six research firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have given a buy recommendation and three have issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $4.75.

Several brokerages recently commented on IBIO. Wall Street Zen upgraded shares of iBio from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Chardan Capital reaffirmed a “buy” rating and issued a $5.00 target price on shares of iBio in a report on Thursday, February 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of iBio in a research report on Monday, December 29th. Lifesci Capital upgraded shares of iBio to a “strong-buy” rating in a report on Thursday, December 18th. Finally, JonesTrading initiated coverage on iBio in a research note on Tuesday, March 3rd. They set a “buy” rating and a $7.00 price target for the company.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Susquehanna International Group LLP bought a new stake in shares of iBio in the 3rd quarter worth approximately $37,000. PFG Investments LLC purchased a new stake in iBio in the 4th quarter worth $41,000. XTX Topco Ltd purchased a new position in shares of iBio during the fourth quarter valued at about $71,000. Persistent Asset Partners Ltd bought a new stake in shares of iBio in the 4th quarter worth about $76,000. Finally, Citadel Advisors LLC bought a new stake in iBio in the third quarter worth about $109,000. Institutional investors own 7.90% of the company’s stock.

iBio Stock Performance

Shares of IBIO stock traded up $0.06 on Thursday, hitting $2.49. The stock had a trading volume of 754,806 shares, compared to its average volume of 1,046,711. iBio has a twelve month low of $0.56 and a twelve month high of $5.60. The company has a fifty day simple moving average of $2.37. The firm has a market cap of $86.00 million, a price-to-earnings ratio of -2.49 and a beta of 1.18.

iBio (NASDAQ:IBIO) last announced its earnings results on Tuesday, February 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01).

iBio Company Profile

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever.